Citadel Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.63M Sell
82,800
-65,100
-44% -$5.37M ﹤0.01% 3883
2025
Q4
$12.6M Buy
147,900
+23,300
+19% +$1.91M ﹤0.01% 2938
2025
Q3
$9.69M Sell
124,600
-30,800
-20% -$2.41M ﹤0.01% 3325
2025
Q2
$12.2M Sell
155,400
-39,900
-20% -$2.98M ﹤0.01% 2762
2025
Q1
$14.2M Sell
195,300
-377,600
-66% -$27M ﹤0.01% 2429
2024
Q4
$42.4M Sell
572,900
-153,600
-21% -$10.8M 0.01% 1431
2024
Q3
$47.9M Buy
726,500
+235,600
+48% +$17.1M 0.01% 1256
2024
Q2
$45.3M Sell
490,900
-448,200
-48% -$39.7M 0.01% 1222
2024
Q1
$89.7M Buy
939,100
+288,100
+44% +$24.2M 0.02% 769
2023
Q4
$49.6M Buy
651,000
+429,800
+194% +$29.9M 0.01% 1190
2023
Q3
$15.3M Buy
221,200
+108,000
+95% +$8.68M ﹤0.01% 2165
2023
Q2
$10.7M Sell
113,200
-495,100
-81% -$43M ﹤0.01% 2592
2023
Q1
$50.3M Buy
608,300
+323,100
+113% +$25.4M 0.01% 1055
2022
Q4
$21.3M Buy
285,200
+18,100
+7% +$1.39M 0.01% 1905
2022
Q3
$22.1M Sell
267,100
-126,200
-32% -$12.1M 0.01% 1775
2022
Q2
$37.4M Buy
393,300
+205,400
+109% +$21.3M 0.01% 1254
2022
Q1
$22.1M Sell
187,900
-124,100
-40% -$13.9M ﹤0.01% 1871
2021
Q4
$40.4M Sell
312,000
-4,100
-1% -$478K 0.01% 1343
2021
Q3
$35.8M Buy
316,100
+62,100
+24% +$7.09M 0.01% 1404
2021
Q2
$26.3M Buy
254,000
+85,000
+50% +$8.01M 0.01% 1758
2021
Q1
$14.1M Sell
169,000
-88,600
-34% -$7.49M ﹤0.01% 2462
2020
Q4
$23.5M Buy
257,600
+25,400
+11% +$2.11M 0.01% 1643
2020
Q3
$18.5M Sell
232,200
-63,500
-21% -$4.95M 0.01% 1650
2020
Q2
$20.4M Buy
295,700
+109,700
+59% +$7.8M 0.01% 1485
2020
Q1
$11.7M Sell
186,000
-194,100
-51% -$14M 0.01% 1703
2019
Q4
$29.6M Sell
380,100
-85,200
-18% -$6.65M 0.01% 1138
2019
Q3
$34.1M Buy
465,300
+173,700
+60% +$12.2M 0.02% 1025
2019
Q2
$18M Sell
291,600
-207,300
-42% -$12.5M 0.01% 1518
2019
Q1
$31.8M Buy
498,900
+269,400
+117% +$15.4M 0.02% 980
2018
Q4
$11.7M Sell
229,500
-186,000
-45% -$9.41M 0.01% 1721
2018
Q3
$24.1M Buy
415,500
+112,200
+37% +$5.49M 0.01% 1249
2018
Q2
$14.7M Buy
303,300
+121,200
+67% +$5.66M 0.01% 1578
2018
Q1
$8.47M Sell
182,100
-125,400
-41% -$5.45M ﹤0.01% 1894
2017
Q4
$11.6M Sell
307,500
-1,200
-0.4% -$44K 0.01% 1589
2017
Q3
$11.2M Buy
308,700
+136,500
+79% +$5.21M 0.01% 1500
2017
Q2
$6.79M Sell
172,200
-94,800
-36% -$3.46M 0.01% 1798
2017
Q1
$8.37M Buy
267,000
+60,900
+30% +$1.91M 0.01% 1572
2016
Q4
$6.44M Buy
206,100
+51,300
+33% +$1.66M 0.01% 1733
2016
Q3
$6.22M Sell
154,800
-91,800
-37% -$3.46M 0.01% 1764
2016
Q2
$8.2M Buy
246,600
+43,800
+22% +$1.5M 0.01% 1400
2016
Q1
$5.96M Buy
202,800
+7,200
+4% +$199K 0.01% 1603
2015
Q4
$5.15M Sell
195,600
-118,800
-38% -$3.09M 0.01% 1796
2015
Q3
$7.45M Sell
314,400
-133,200
-30% -$3.21M 0.01% 1572
2015
Q2
$10.6M Buy
447,600
+211,200
+89% +$4.77M 0.01% 1435
2015
Q1
$5.61M Sell
236,400
-60,000
-20% -$1.35M 0.01% 1917
2014
Q4
$6.29M Buy
296,400
+82,800
+39% +$1.66M 0.01% 1773
2014
Q3
$3.64M Buy
213,600
+1,800
+0.8% +$28.4K ﹤0.01% 2272
2014
Q2
$3.03M Sell
211,800
-68,400
-24% -$927K ﹤0.01% 2326
2014
Q1
$3.46M Sell
280,200
-241,200
-46% -$2.78M ﹤0.01% 2092
2013
Q4
$5.71M Buy
521,400
+178,800
+52% +$2.02M 0.01% 1585
2013
Q3
$3.98M Sell
342,600
-52,200
-13% -$611K 0.01% 1765
2013
Q2
$4.42M Buy
+394,800
New +$4.67M 0.01% 1688

Other funds holding EW

Citadel Advisors's EW Position: Q1 2026 in Review

Citadel Advisors reduced its Edwards Lifesciences (EW) stake by 76% in Q1 2026, selling an estimated $139M and leaving 519,031 shares worth $41.6M. The position accounts for 0.01% of the portfolio, ranked #1533.

Citadel Advisors first reported a position in EW in Q2 2013 and has held it in 51 quarters since. The position peaked at $996M in Q2 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Citadel Advisors held 519,031 shares of Edwards Lifesciences worth $41.6M as of Q1 2026.
  • Citadel Advisors sold 1,684,896 Edwards Lifesciences shares in Q1 2026, an estimated $139M.
  • Edwards Lifesciences made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1533 holding.
  • Citadel Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 51 quarters since.
  • Citadel Advisors's Edwards Lifesciences position peaked at $996M in Q2 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.